Arrowhead Pharmaceuticals, Inc. (ARWR)
After hours:
| Previous close | 45.63 |
| Open | 46.16 |
| Bid | 47.00 x 900 |
| Ask | 48.00 x 1400 |
| Day's range | 46.06 - 47.90 |
| 52-week range | 26.81 - 84.83 |
| Volume | |
| Avg. volume | 835,722 |
| Market cap | 5.006B |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.08 |
| Earnings date | 04 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 77.25 |
- Motley Fool
Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript
Thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 third quarter ended June 30, 2022. With us today from management are president and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our chief medical officer, who will provide an update on our mid-and later-stage clinical pipeline; Dr. James Hamilton, our senior vice president of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our chief financial officer, who will give a review of the financials.
- Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
PASADENA, Calif., August 04, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30 p.m. ET to discuss the results.
- Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
PASADENA, Calif., July 20, 2022--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022.
